Dasatinib in chronic myeloid leukemia: a review

References

• GoldmanJMMeloJVChronic myeloid leukemia–advances in biology and new approaches to treatmentN Engl J Med20033491451146414534339
   PubMed Web of Science ®Google Scholar
• KurzrockRGuttermanJUTalpazMThe molecular genetics of Philadelphia chromosome-positive leukemiasN Engl J Med19883199909983047582
   PubMed Web of Science ®Google Scholar
• CalabrettaBPerrottiDThe biology of CML blast crisisBlood20041034010402214982876
   PubMed Web of Science ®Google Scholar
• DrukerBJTamuraSBuchdungerEEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cellsNat Med199625615668616716
   PubMed Web of Science ®Google Scholar
• SawyersCLChronic myeloid leukemiaN Engl J Med19993401330134010219069
   PubMed Web of Science ®Google Scholar
• CohenMHWilliamsGJohnsonJRApproval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemiaClin Cancer Res2002893594212006504
   PubMed Web of Science ®Google Scholar
• Gambacorti-PasseriniCle CoutrePMologniLInhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosisBlood Cells Mol Dis1997233803949446752
   PubMed Web of Science ®Google Scholar
• DrukerJO’BrienSLarsonRALong-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): The 5-year update from the IRIS studyJ Clin Oncol(Meeting Abstracts)20062418S P1 Abstract 6506.
   Google Scholar
• HochhausADrukerBJLarsonRO’BrienSGGathmannIGuilhotFIRIS 6-year follow-up: Sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (abstract 25)Blood200711016a
   Web of Science ®Google Scholar
• O’BrienSGGuilhotFLarsonRAImatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemiaN Engl J Med2003348994100412637609
   PubMed Web of Science ®Google Scholar
• BaccaraniMSaglioGGoldmanJEvolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetBlood20061081809182016709930
   PubMed Web of Science ®Google Scholar
• ShahNPSawyersCLMechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemiasOncogene2003227389739514576846
   PubMed Web of Science ®Google Scholar
• GorreMEMohammedMEllwoodKClinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplificationScience200129387688011423618
   PubMed Web of Science ®Google Scholar
• SoveriniSMartinelliGRostiGABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid LeukemiaJ Clin Oncol2005234100410915867198
   PubMed Web of Science ®Google Scholar
• Cowan-JacobSWGuezVFendrichGImatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatmentMini Rev Med Chem2004428529915032675
   PubMed Web of Science ®Google Scholar
• HochhausAKreilSCorbinASMolecular and chromosomal mechanisms of resistance to imatinib (STI571) therapyLeukemia2002162190219612399961
   PubMed Web of Science ®Google Scholar
• IllmerTSchaichMPlatzbeckerUP-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylateLeukemia20041840140814724652
   PubMed Web of Science ®Google Scholar
• ThomasJWangLClarkREPirmohamedMActive transport of imatinib into and out of cells: implications for drug resistanceBlood20041043739374515315971
   PubMed Web of Science ®Google Scholar
• Gambacorti-PasseriniCBarniRle CoutrePRole of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571J Natl Cancer Inst2000921641165011036109
   PubMed Web of Science ®Google Scholar
• BurgerHvan TolHBoersmaAWImatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pumpBlood20041042940294215251980
   PubMed Web of Science ®Google Scholar
• RixUHantschelODurnbergerGChemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targetsBlood20071104055406317720881
   PubMed Web of Science ®Google Scholar
• ShahNPTranCLeeFYChenPNorrisDSawyersCLOverriding imatinib resistance with a novel ABL kinase inhibitorScience200430539940115256671
   PubMed Web of Science ®Google Scholar
• O’HareTWaltersDKStoffregenEPIn vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutantsCancer Res2005654500450515930265
   PubMed Web of Science ®Google Scholar
• MullerMCCortesJKimD-WDasatinib efficacy in patients with chronic myeloid leukemia in chronic phase and preexisting BCR-ABL mutations (abstract 449)Blood200811211171
   Web of Science ®Google Scholar
• RedaelliSPiazzaRRostagnoRActivity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutantsJ Clin Oncol20092746947119075254
   PubMed Web of Science ®Google Scholar
• ApperleyJFPart I: mechanisms of resistance to imatinib in chronic myeloid leukaemiaLancet Oncol200781018102917976612
   PubMed Web of Science ®Google Scholar
• TokarskiJSNewittJAChangCYThe structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutantsCancer Res2006665790579716740718
   PubMed Web of Science ®Google Scholar
• BraveMGoodmanVKaminskasESprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylateClin Cancer Res20081435235918223208
   PubMed Web of Science ®Google Scholar
• LombardoLJLeeFYChenPDiscovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assaysJ Med Chem2004476658666115615512
   PubMed Web of Science ®Google Scholar
• KonigHCoplandMChuSJoveRHolyoakeTLBhatiaREffects of dasatinib on Src kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cellsCancer Res2008689624963319047139
   PubMed Web of Science ®Google Scholar
• ShahNPKasapCWeierCTransient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosisCancer Cell20081448549319061839
   PubMed Web of Science ®Google Scholar
• CoplandMHamiltonAElrickLJDasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fractionBlood20061074532453916469872
   PubMed Web of Science ®Google Scholar
• KimDHKamel-ReidSChangHNatural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemiaHaematologica20099413513919066329
   PubMed Web of Science ®Google Scholar
• PorkkaKKoskenvesaPLundanTDasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemiaBlood20081121005101218477770
   PubMed Web of Science ®Google Scholar
• KamathAVWangJLeeFYMarathePHPreclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against Src and BCR-ABLCancer Chemother Pharmacol20086136537617429625
   PubMed Web of Science ®Google Scholar
• BrendelCScharenbergCDohseMImatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cellsLeukemia2007211267127517519960
   PubMed Web of Science ®Google Scholar
• TalpazMShahNPKantarjianHDasatinib in imatinib-resistant Philadelphia chromosome-positive leukemiasN Engl J Med20063542531254116775234
   PubMed Web of Science ®Google Scholar
• GuilhotFApperleyJKimDWDasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phaseBlood20071094143415017264298
   PubMed Web of Science ®Google Scholar
• CortesJRousselotPKimDWDasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisisBlood20071093207321317185463
   PubMed Web of Science ®Google Scholar
• HochhausAKantarjianHMBaccaraniMDasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapyBlood20071092303230917138817
   PubMed Web of Science ®Google Scholar
• KantarjianHPasquiniRHamerschlakNDasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trialBlood20071095143515017317857
   PubMed Web of Science ®Google Scholar
• OttmannODombretHMartinelliGDasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 studyBlood20071102309231517496201
   PubMed Web of Science ®Google Scholar
• ShahNPKantarjianHMKimDWIntermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemiaJ Clin Oncol2008263204321218541900
   PubMed Web of Science ®Google Scholar
• Quintas-CardamaAKantarjianHJonesDDasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failureBlood200710949749916990591
   PubMed Web of Science ®Google Scholar
• CangSLiuDP-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemiaJ Hematol Oncol200811518828913
   PubMed Web of Science ®Google Scholar
• JonesDKamel-ReidSBahlerDLaboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular PathologyJ Mol Diagn20091141119095773
   PubMed Web of Science ®Google Scholar
• HughesTDeiningerMHochhausAMonitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing resultsBlood2006108283716522812
   PubMed Web of Science ®Google Scholar
• SoveriniSMartinelliGColarossiSPresence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemiaJ Clin Oncol200624e51e217114651
   PubMedGoogle Scholar
• MeloJChuahCNovel agents in CML therapy: tyrosine kinase inhibitors and beyondAm Soc Hematol2008427435
   PubMedGoogle Scholar
• CoplandMPellicanoFRichmondLBMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitorsBlood20081112843285318156496
   PubMed Web of Science ®Google Scholar
• HochhausABaccaraniMDeiningerMDasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinibLeukemia2008221200120618401416
   PubMed Web of Science ®Google Scholar
• CortesJKimDWRaffouxEEfficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phaseLeukemia2008222176218318754032
   PubMed Web of Science ®Google Scholar